CA
IMVT icon

CoreCap Advisors’s Immunovant IMVT Stock Holding History

CoreCap Advisors’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-55
Closed -$1.4K – 3007
2025
Q4 		$1.4K Hold
55
– – ﹤0.01% 2542
2025
Q3 		$887 Hold
55
– – ﹤0.01% 2501
2025
Q2 		$880 Sell
55
-5,779
-99% -$87.4K ﹤0.01% 2441
2025
Q1 		$99.7K Buy
5,834
+2,401
+70% +$50.2K ﹤0.01% 911
2024
Q4 		$85K Sell
3,433
-924
-21% -$26.2K ﹤0.01% 986
2024
Q3 		$124K Sell
4,357
-3,368
-44% -$99.3K 0.01% 832
2024
Q2 		$204K Sell
7,725
-313
-4% -$8.9K 0.02% 367
2024
Q1 		$260K Buy
8,038
+1,631
+25% +$59.5K 0.01% 558
2023
Q4 		$270K Buy
6,407
+647
+11% +$23.8K 0.02% 490
2023
Q3 		$221K Sell
5,760
-9,652
-63% -$218K 0.02% 481
2023
Q2 		$292K Buy
+15,412
New +$287K 0.02% 457

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

CoreCap Advisors's IMVT Position: Q1 2026 in Review

CoreCap Advisors sold out of Immunovant (IMVT) in Q1 2026, closing a stake of 55 shares — an estimated $1.4K sold.

CoreCap Advisors first reported a position in IMVT in Q2 2023 and held it in 11 quarters. The position peaked at $292K in Q2 2023. 215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • CoreCap Advisors reported no remaining Immunovant position as of Q1 2026 after selling out during the quarter.
  • CoreCap Advisors sold 55 Immunovant shares in Q1 2026, an estimated $1.4K.
  • CoreCap Advisors first reported a position in Immunovant in Q2 2023 and held it in 11 quarters.
  • CoreCap Advisors's Immunovant position peaked at $292K in Q2 2023.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on CoreCap Advisors's 13F filing for Q1 2026, filed 7 Apr 2026.